drugset / Trial / NCT01349829

A Study to Evaluate the Safety and Immunogenicity of the Hepatitis A Virus Vaccine HAVpur in Healthy Young Children

NCT01349829

Phase 4 Completed 251 enrolled Crucell Holland BV
RandomizedParallel-groupOpen-labelPrevention

Summary

This is a study to test whether vaccination with HAVpur Junior against hepatitis A provides protection that is non-inferior to the protection afforded by vaccination with Havrix 720 Junior.

Timeline

Start
2010-03
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject HAVpur Vaccine 12 iu Intramuscular
Comparator Havrix Vaccine 720 unknown Intramuscular